A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)

Study type

Interventional

Primary purpose

Treatment

Allocation

Randomized

Intervention model

Parallel

Masking

Single

Arms

3

Interventions

• MK-1045 Biological
• Blinatumomab Biological
• Acetaminophen Drug
• Diphenhydramine Drug
• Dexamethasone Drug
• Tocilizumab Drug
• Siltuximab Drug
• Avtozma Drug
• Tyenne Drug

• B-cell Acute Lymphoblastic Leukemia

Primary outcome

Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2 (3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)); Percentage of Participants Who Experience an Adverse Event (AE) in Study Part 1 (3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)); Percentage of Participants Who Discontinue Study Intervention Due to an AE in Study Part 1 (3 treatment cycles (up to approximately 126 days; each cycle is up to 42 days; cycle lengths vary between cycle and arm)); Overall Survival (OS) in Study Part 2 (Up to approximately 7 years)

• MK-1045

• NCT07570173 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read 41 min ago

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.